SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 2000

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Kidney Cancer
Interventions
BIOLOGICAL

recombinant interferon alfa

DRUG

semaxanib

Trial Locations (3)

95817

University of California Davis Cancer Center, Sacramento

91010-3000

Cancer Center and Beckman Research Institute, City of Hope, Duarte

90033-0804

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00006384 - SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter